儿童抗菌药物耐药性的全球趋势与至2035年预测
Access组抗生素耐药均值36%,Watch组22%,Reserve组13%。预测至2035年Klebsiella碳青霉烯耐药达35%,A. baumannii达82%。
要点
- 2004至2022年所有区域儿童AMR均上升,资源有限地区耐药水平更高且增长更快。
- ICU中Watch组耐药从15%升至33%,0-2岁、脓毒症及呼吸道感染增长显著。
- 预测至2035年Klebsiella碳青霉烯耐药35%,A. baumannii达82%。
核心结论
- 研究期间所有区域的儿童抗菌药物耐药性均增加,主要由导致脓毒症和肺炎的革兰阴性病原体耐药上升驱动。
- 这些趋势威胁儿童严重感染经验性治疗的有效性,尤其在替代治疗选择有限的环境中。
研究设计与样本
- 数据分析时间为2024年2月至2026年4月。
主要发现
- 对任何Access组抗生素的耐药总体最高,均值为36%(范围2%-66%);Watch组均值为22%(范围1%-47%);Reserve组均值为13%(范围0%-30%)。
- ICU中Watch组抗生素耐药从15%(517/3564)升至33%(2910/8748)(P < .001),0至2岁组从12%(325/2649)升至32%(1257/3959)(P < .001)。
- ICU中脓毒症患儿Watch组耐药从15%(298/2030)升至30%(1409/4705)(P < .001),呼吸道感染患儿从12%(657/5324)升至29%(3311/11507)(P < .001)。
- Acinetobacter baumannii总体耐药最高(每个AWaRe类别均超过55%),Klebsiella species增长最快,尤其在东南亚、东欧和西太平洋地区对第三代或第四代头孢菌素和碳青霉烯类。
关键数值与推荐
- 预测至2035年,Klebsiella species碳青霉烯耐药为35%(95%不确定性区间29%-40%),A baumannii为82%(95%不确定性区间77%-85%)。
- 预测显示Access组抗生素耐药趋于稳定,但Watch组和Reserve组抗生素耐药继续增加,尤其是革兰阴性病原体。
临床怎么用
- 儿童严重感染经验性治疗需考虑革兰阴性病原体耐药上升趋势,尤其在ICU、0至2岁、脓毒症和呼吸道感染患儿中。
- 资源有限地区应关注Watch组和Reserve组抗生素耐药快速增长,合理使用AWaRe分类指导抗生素选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Antimicrobial resistance (AMR) threatens effective treatment of severe childhood infections, but multiregional data about pediatric AMR remain limited. OBJECTIVE: To assess geographic and temporal AMR trends among children for World Health Organization (WHO) priority pathogens using the WHO Access, Watch, and Reserve (AWaRe) antibiotic classification. DESIGN, SETTING, AND PARTICIPANTS: This multiregional surveillance study analyzed pediatric bacterial isolates from the Antimicrobial Testing Leadership and Surveillance (ATLAS) database between January 2004 and December 2022. The analysis included 106 581 isolates from 106 581 children aged 0 to 18 years in 82 countries. Data were analyzed from February 2024 to April 2026. EXPOSURES: Resistance to AWaRe-categorized antibiotics in WHO priority bacterial pathogens. MAIN OUTCOMES AND MEASURES: Temporal trends in resistance were evaluated using linear and nonlinear models, by geographic region, age, setting, and infection. Spatiotemporal generalized additive models were applied to estimate resistance trajectories and forecast to 2035. RESULTS: Of 106 581 children included in this study, 47% were aged 0 to 2 years, 35% were aged 3 to 12 years, and 18% were aged 13 to 18 years; 58 620 (55%) were male. From 2004 to 2022, pediatric AMR increased in all regions, with consistently higher resistance levels and faster growth in resource-limited settings. Resistance to any Access-group antibiotic was highest overall at a mean of 36% (range, 2%-66%), with resistance to Watch-group antibiotics at a mean of 22% (range, 1%-47%) and Reserve-group antibiotics at a mean of 13% (range, 0%-30%). Resistance to antibiotics in the Watch and Reserve groups increased most rapidly in intensive care units, wherein Watch-group antibiotic resistance increased from 15% (517/3564) to 33% (2910/8748) (P < .001), especially in those aged 0 to 2 years (12% [325/2649] to 32% [1257/3959]; P < .001) and those with sepsis (15% [298/2030] to 30% [1409/4705]; P < .001) and respiratory infections [12% [657/5324] to 29% [3311/11507]; P < .001). Acinetobacter baumannii had the highest overall resistance (more than 55% in every AWaRe category), while Klebsiella species increased fastest, particularly to third- or fourth-generation cephalosporins and carbapenems in Southeast Asia, Eastern Europe, and the Western Pacific. Projections suggested stabilization of resistance to Access antibiotics but continued increases in resistance to antibiotics in the Watch and Reserve groups, especially in Gram-negative pathogens. By 2035, carbapenem resistance was projected to be 35% (95% uncertainty interval [UI], 29%-40%) in Klebsiella species and 82% (95% UI, 77%-85%) in A baumannii. CONCLUSIONS AND RELEVANCE: Pediatric AMR increased in all regions across the study period, driven primarily by escalating resistance among Gram-negative pathogens responsible for sepsis and pneumonia. These trends threaten the effectiveness of empiric therapy for severe childhood infections, particularly in settings with limited alternative treatment options.
引用
- Hu YJ, Qiu H, Harwell JI, et al. Childhood Antimicrobial Resistance With Global Forecasts. JAMA Pediatr. 2026. PMID: 42475107. doi:10.1001/jamapediatrics.2026.2808
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。